Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (81-90 of 154) with videos related to

Pageof 16
Sort By:
Cancers|April 3, 2021
OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational EvidenceFrancesca Megiorni, Simona Camero, Paola Pontecorvi, et al.
Oncotarget|September 29, 2018
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II studyFrancesca De Felice, Giancarlo D'Ambrosio, Daniela Musio, et al.
Plos One|June 24, 2015
Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 PatientsMario Di Staso, Giovanni Luca Gravina, Luigi Zugaro, et al.
Oncology Reports|July 8, 2022
Anti‑oncogenic and pro‑myogenic action of the MKK6/p38/AKT axis induced by targeting MEK/ERK in embryonal rhabdomyosarcomaAgnese Di Rocco, Simona Camero, Anna Benedetti, et al.
Oncotarget|April 19, 2017
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma modelsGiovanni Luca Gravina, Andrea Mancini, Claudia Mattei, et al.
Cancers|August 29, 2024
Correction: Gravina et al. ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma. <i>Cancers</i> 2022, <i>14</i>, 289Giovanni Luca Gravina, Alessandro Colapietro, Andrea Mancini, et al.
Journal of Neuro-Oncology|November 14, 2024
Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocolPaolo Tini, Elisa Cinelli, Mariya Yavorska, et al.
European Journal of Pharmacology|May 11, 2022
Interaction of the preferential D<sub>3</sub> agonist (+)PHNO with dopamine D<sub>3</sub>-D<sub>2</sub> receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imagingFrancesco Petragnano, Irene Fasciani, Clotilde Mannoury la Cour, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 23, 2017
The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical modelsGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
International Journal of Molecular Sciences|November 11, 2022
Translational Implications for Radiosensitizing Strategies in RhabdomyosarcomaSilvia Pomella, Antonella Porrazzo, Matteo Cassandri, et al.
Pageof 16

Showing results (81-90 of 154) with videos related to

Sort By:
Pageof 16
Cancers|April 3, 2021
OTX015 Epi-Drug Exerts Antitumor Effects in Ovarian Cancer Cells by Blocking GNL3-Mediated Radioresistance Mechanisms: Cellular, Molecular and Computational EvidenceFrancesca Megiorni, Simona Camero, Paola Pontecorvi, et al.
Oncotarget|September 29, 2018
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II studyFrancesca De Felice, Giancarlo D'Ambrosio, Daniela Musio, et al.
Plos One|June 24, 2015
Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 PatientsMario Di Staso, Giovanni Luca Gravina, Luigi Zugaro, et al.
Oncology Reports|July 8, 2022
Anti‑oncogenic and pro‑myogenic action of the MKK6/p38/AKT axis induced by targeting MEK/ERK in embryonal rhabdomyosarcomaAgnese Di Rocco, Simona Camero, Anna Benedetti, et al.
Oncotarget|April 19, 2017
Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma modelsGiovanni Luca Gravina, Andrea Mancini, Claudia Mattei, et al.
Cancers|August 29, 2024
Correction: Gravina et al. ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma. <i>Cancers</i> 2022, <i>14</i>, 289Giovanni Luca Gravina, Alessandro Colapietro, Andrea Mancini, et al.
Journal of Neuro-Oncology|November 14, 2024
Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocolPaolo Tini, Elisa Cinelli, Mariya Yavorska, et al.
European Journal of Pharmacology|May 11, 2022
Interaction of the preferential D<sub>3</sub> agonist (+)PHNO with dopamine D<sub>3</sub>-D<sub>2</sub> receptor heterodimers and diverse classes of monoamine receptor: relevance for PET imagingFrancesco Petragnano, Irene Fasciani, Clotilde Mannoury la Cour, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 23, 2017
The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical modelsGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
International Journal of Molecular Sciences|November 11, 2022
Translational Implications for Radiosensitizing Strategies in RhabdomyosarcomaSilvia Pomella, Antonella Porrazzo, Matteo Cassandri, et al.
Pageof 16